Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$70.81 USD
+0.85 (1.21%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $70.85 +0.04 (0.06%) 7:38 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Gilead Sciences (GILD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$84.46 | $119.00 | $69.00 | 20.73% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Gilead Sciences comes to $84.46. The forecasts range from a low of $69.00 to a high of $119.00. The average price target represents an increase of 20.73% from the last closing price of $69.96.
Analyst Price Targets (24)
Broker Rating
Gilead Sciences currently has an average brokerage recommendation (ABR) of 2.12 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 2.20 a month ago based on 25 recommendations.
Of the 26 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 42.31% and 3.85% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/GILD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 10 | 10 | 10 |
Buy | 1 | 0 | 0 | 0 | 0 |
Hold | 14 | 15 | 15 | 15 | 14 |
Sell | 0 | 0 | 0 | 0 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.12 | 2.15 | 2.20 | 2.20 | 2.24 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/8/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
6/26/2024 | Atlantic Equities | Simon Baker | Not Available | Strong Buy |
6/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/20/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Hold |
5/1/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
4/29/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/26/2024 | Truist Securities | Asthika S Goonewardene | Hold | Hold |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/24/2024 | Not Identified | Not Identified | Moderate Sell | Hold |
4/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
3/15/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
3/4/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
2/22/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/12/2024 | Needham & Company | Joseph R Stringer | Not Available | Hold |
2/7/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
2/7/2024 | UBS | Colin N Bristow | Not Available | Hold |
2/7/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
10/11/2023 | SVB Securities | Daina M Graybosch | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.12 |
ABR (Last week) | 2.15 |
# of Recs in ABR | 26 |
Average Target Price | $84.46 |
LT Growth Rate | 6.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | 1.58 |